Rexahn in-Licenses Novel Oligonucleotide Targeted Drug Delivery Platform From Ohio State University
Rexahn In-Licenses Novel Oligonucleotide Targeted Drug Delivery Platform from Ohio State University – Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company, announced today that it has signed an exclusive license agreement w…
Leave a Reply
You must be logged in to post a comment.